TriOx Blood Test: Early Cancer Detection With High Accuracy

TriOx, a new blood test uses advanced circulating tumor DNA (ctDNA) analysis and machine learning approach to detect six cancer types early with high sensitivity and specificity.

TriOx, a novel blood test shows potential in detecting cancer among six cancer types including colorectal, esophageal, pancreatic, renal, ovarian, and breast cancer.

The study conducted by Oxford researchers and published in Nature Communications, showed that TriOx analyses multiple features of ctDNA in the blood to identify cancer from its early stages. It offers a rapid, sensitive, and minimally invasive which can replace the traditional diagnostic methods. It can also differentiate individuals with a history of cancer from those without.

Breast Cancer Risk Assessment Calculator
Breast Cancer Risk Assessment Calculator predicts the risk for breast cancer. Find list of breast cancer facts and more information on signs and symptoms of breast cancer and mammography.

‘#TriOx, a minimally invasive cancer detection blood test can identify #cancer faster and more accurately than traditional methods. #liquidbiopsy #medindia ’

How TriOx Blood Test Detects Cancer Fast and Accurate

Traditional tests use only one or two features of ctDNA. But, TriOx uses an advanced ctDNA analysis technique called (TAPS) combined with machine learning to identify multiple features of circulating DNA in the blood. This makes the test highly sensitive and reliable.

The test was evaluated using blood samples from patients with and without cancer referred by their general physician. TriOx detected cancer with 94.9% sensitivity (correctly identifying people with cancer) and 88.8% specificity (correctly identifying those without cancer). This reduces the time to test healthy individuals while ensuring cancer patients get timely treatment.

TriOx: The Future of Early Cancer Diagnosis

This test could revolutionize cancer detection by making regular blood tests for cancer as simple as the tests available to measure the cholesterol or blood sugar. Early detection of cancer improves patient survival and lowers the treatment expense.

Cell-Free DNA (cfDNA) Application in Cancer Detection
cfDNA offers a non-invasive approach for early cancer detection, monitoring treatment response, and identifying relapses, aiding in improved patient outcomes.

While TriOx is under development, researchers are expanding its testing to include more cancer types and larger patient groups. Successful results of this study could enable early cancer identification and save millions of lives worldwide.

Cell-free DNA: A Non-Invasive Cancer Detection
Cell-free DNA can be used for non-invasive cancer detection and disease monitoring to enhance personalized medicine.

Source-Medindia

Circulating Cell-Free DNA Is Enabling Early Lung Cancer Diagnosis
Circulating cell-free DNA (cfDNA) analysis offers a non-invasive way to identify lung cancer, even at early stages, through DNA fragments in the bloodstream.